A Clinical Trial With a New Needle Device Comparing Two Needles for EUS_FNA of Solid Lesions. (EUS-FNA)
Primary Purpose
Pancreatic Cancer, Neuroendocrine Tumors, Lymphadenopathies
Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
25G needle
22G needle
Sponsored by
About this trial
This is an interventional diagnostic trial for Pancreatic Cancer focused on measuring Pancreatic cancer, Neuroendocrine tumors, Lymphadenopathies, GIST, Gastrointestinal wall neoplasia
Eligibility Criteria
Inclusion Criteria:
- endosonographic appearance of a solid lesions
- age >18 years
- informed consent.
Exclusion Criteria:
- alteration of the coagulation (INR >1.5, PLT <50 x 103 /µL)
- inability to express consent
Sites / Locations
- Humanitas Research HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
25G needle
22G needle
Arm Description
All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
Outcomes
Primary Outcome Measures
Clinical performance of 22G and 25G needles
Evaluation of whether enough material for adequate cytological/histological analysis can obtained with equal efficacy with the 25G and the 22G needles. The percentages of adequate samples obtained.
Secondary Outcome Measures
Ease of needle pass
The subjective evaluation of the operator (easy or hard)
Needle malfunction
Needles do not come out of the cover; kinking; needles do not puncture the tissue (presence or absence of malfunction, and registering of the specific malfunction)
Number of passes
The total number of passes needed to obtain adequate material for each lesion (absolute number).
Number of crossovers
The times when the need for passage from the 22G to the 25G needle, or vice versa, registered as percentages of the total procedures.
Major complications
Bleeding (minor: visible at EUS but without clinical significance or less than 2 g/dl; major: dropping of more than 2 g/dl in Hb levels and clinically significant), perforation (presence/absence), infection (need for hospitalization).
Full Information
NCT ID
NCT02246322
First Posted
September 1, 2014
Last Updated
September 18, 2014
Sponsor
Istituto Clinico Humanitas
1. Study Identification
Unique Protocol Identification Number
NCT02246322
Brief Title
A Clinical Trial With a New Needle Device Comparing Two Needles for EUS_FNA of Solid Lesions.
Acronym
EUS-FNA
Official Title
A Randomized Clinical Trial With a New Needle Device Comparing 25G and 22G Needle in Endoscopic Ultrasound Fine-needle Aspiration of Solid Lesions.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2014
Overall Recruitment Status
Unknown status
Study Start Date
August 2013 (undefined)
Primary Completion Date
October 2014 (Anticipated)
Study Completion Date
November 2014 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Istituto Clinico Humanitas
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) is a reliable, safe, and effective technique for obtaining samples from the GI wall lesions and from organs adjacent to the GI tract (pancreas, nodes...).Needles available for EUS-FNA include 25G, 22G and 19G. Some studies have suggested that the 25G needle could be equal or even better than the 22G needle.
The BXN system and neddles are is a newly developed for EUS-FNA. This trial is developed for testing the accuracy of the new neddle system for EUS-FNA and for comparing the two needles types, 25G and 22G.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Cancer, Neuroendocrine Tumors, Lymphadenopathies, GIST, Gastric Wall Tumor
Keywords
Pancreatic cancer, Neuroendocrine tumors, Lymphadenopathies, GIST, Gastrointestinal wall neoplasia
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
144 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
25G needle
Arm Type
Experimental
Arm Description
All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
Arm Title
22G needle
Arm Type
Experimental
Arm Description
All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
Intervention Type
Device
Intervention Name(s)
25G needle
Intervention Description
All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
Intervention Type
Device
Intervention Name(s)
22G needle
Intervention Description
All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
Primary Outcome Measure Information:
Title
Clinical performance of 22G and 25G needles
Description
Evaluation of whether enough material for adequate cytological/histological analysis can obtained with equal efficacy with the 25G and the 22G needles. The percentages of adequate samples obtained.
Time Frame
18 months
Secondary Outcome Measure Information:
Title
Ease of needle pass
Description
The subjective evaluation of the operator (easy or hard)
Time Frame
18 months
Title
Needle malfunction
Description
Needles do not come out of the cover; kinking; needles do not puncture the tissue (presence or absence of malfunction, and registering of the specific malfunction)
Time Frame
18 months
Title
Number of passes
Description
The total number of passes needed to obtain adequate material for each lesion (absolute number).
Time Frame
18 months
Title
Number of crossovers
Description
The times when the need for passage from the 22G to the 25G needle, or vice versa, registered as percentages of the total procedures.
Time Frame
18 months
Title
Major complications
Description
Bleeding (minor: visible at EUS but without clinical significance or less than 2 g/dl; major: dropping of more than 2 g/dl in Hb levels and clinically significant), perforation (presence/absence), infection (need for hospitalization).
Time Frame
18 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
endosonographic appearance of a solid lesions
age >18 years
informed consent.
Exclusion Criteria:
alteration of the coagulation (INR >1.5, PLT <50 x 103 /µL)
inability to express consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Silvia Carrara, MD
Phone
+390282247288
Email
silvia.carrara@humanitas.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Silvia Carrara, MD
Organizational Affiliation
Humanitas Research Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Humanitas Research Hospital
City
Rozzano, Milan
ZIP/Postal Code
20089
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alessandro Repici, MD
Phone
+390282247493
Email
alessadro.repici@humanitas.it
First Name & Middle Initial & Last Name & Degree
Silvia Carrara, MD
12. IPD Sharing Statement
Citations:
PubMed Identifier
21611946
Citation
Camellini L, Carlinfante G, Azzolini F, Iori V, Cavina M, Sereni G, Decembrino F, Gallo C, Tamagnini I, Valli R, Piana S, Campari C, Gardini G, Sassatelli R. A randomized clinical trial comparing 22G and 25G needles in endoscopic ultrasound-guided fine-needle aspiration of solid lesions. Endoscopy. 2011 Aug;43(8):709-15. doi: 10.1055/s-0030-1256482. Epub 2011 May 24.
Results Reference
background
PubMed Identifier
19640524
Citation
Siddiqui UD, Rossi F, Rosenthal LS, Padda MS, Murali-Dharan V, Aslanian HR. EUS-guided FNA of solid pancreatic masses: a prospective, randomized trial comparing 22-gauge and 25-gauge needles. Gastrointest Endosc. 2009 Dec;70(6):1093-7. doi: 10.1016/j.gie.2009.05.037. Epub 2009 Jul 28.
Results Reference
background
Learn more about this trial
A Clinical Trial With a New Needle Device Comparing Two Needles for EUS_FNA of Solid Lesions.
We'll reach out to this number within 24 hrs